Multi-field-of-view SPECT is superior to whole-body scanning for assessing metastatic bone disease in patients with prostate cancer - Abstract

Department of Nuclear Medicine and PET/CT Center, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.

Department of Nuclear Medicine, IRCCS Ospedale Maggiore, Milan; Department of Diagnostic Services, Unit of Nuclear Medicine, San Paolo Hospital, Milan; Department of Biomedical Sciences and Technologies and Center of Molecular and Cellular Imaging (IMAGO), University of Milan, Milan, Italy.



The aim of this study was to compare the diagnostic performance of whole-body bone scintigraphy (WBS) and multi-field-of-view single photon emission tomography (multi-FOV SPECT) with 99mTc-oxidronate (99mTc-HDP) in patients with prostate cancer (PCa).

In a prospective study, WBS and SPECT acquisitions were performed in 194 patients with histologically confirmed PCa and serum prostate-specific antigen (PSA) levels above 10 ng/mL. Scans obtained using the two modalities were interpreted separately. Clinical and biochemical follow-up, radiological studies and biopsies served as benchmarks for the assessments. The impact of PSA level on WBS and SPECT results was also evaluated.

The patient-based sensitivity, specificity, accuracy, PPV and NPV values of SPECT examinations were higher than those of WBS, especially in patients with serum PSA levels < 40 ng/mL.

Multi-FOV SPECT proved to be more sensitive and specific than WBS in detecting bone metastases in PCa patients.

Written by:
Giovanella L, Castellani M, Suriano S, Ruberto T, Ceriani L, Tagliabue L, Lucignani G.   Are you the author?

Reference: Tumori. 2011 Sep-Oct;97(5):629-33.
doi: 10.1700/989.10723

PubMed Abstract
PMID: 22158495 Prostate Cancer Section